Pharm-Olam International to Host Pharmaceutical and Biotech Professionals at May 15th Live Webinar in Preparation for GDPR Implementation Across Global Clinical Trials

Share Article

The Global CRO to lead a discussion and interactive forum on impacts of GDPR, and what sponsors can do to prepare for the industry-changing data privacy and protection regulations.

Pharm-Olam International logo

Global CRO Pharm-Olam International to host interactive webinar on impacts of GDPR, and what sponsors can do to prepare for the industry-changing data privacy and protection regulations.

"Pharm-Olam is fully prepared for the global GDPR roll-out, and we can help sponsors do the same." — Daniel Burgess, FRQA, Chief Compliance Officer at Pharm-Olam International

Pharm-Olam International, a global, full-service Contract Research Organization (CRO) specializing in Oncology, Infectious Diseases & Vaccines, Rare Diseases and Pediatric indications, as well as General Medicine and U.S. Government-sponsored research, is prepared for the implementation of the European Union’s (EU’s) General Data Protection Regulation (GDPR), it announced today, and will share its implementation methods and best practices at a live, interactive webinar on May 15.

GDPR, which will take effect on May 25, is a strict set of new rules concerning privacy and data security in the EU. It affects anyone holding data on EU citizens—including those companies not based in the EU— and imposes strict penalties on violators.
While the new regulation is intended to unify data protection laws and requirements to ensure each citizen’s personal data is completely secure, it also presents challenges and risk exposures for companies throughout the healthcare industry.

In anticipation of GDPR’s effective date, Pharm-Olam will host an interactive 60-minute live training webinar on May 15, 2018 at 11 a.m. EST for its pharmaceutical and biotechnology partners and clients. The focus of the webinar will be on GDPR compliance and the steps organizations can take to do so, while also demonstrating Pharm-Olam’s risk management process—a “visual Bow Tie Methodology”—and how it forms the foundation for organizational compliance with GDPR.

“We suspect most organizations in our industry are not ready for the ramifications of what GDPR brings and how it impacts a company at the organizational level and at the clinical trial conduct level. Pharm-Olam has been preparing for GDPR compliance for months, and we want to share this with the industry while also demonstrating our use of the Bow Tie Methodology for visual risk assessment and management. Pharm-Olam is fully prepared for the global GDPR roll-out, and we can help sponsors do the same,” said Daniel Burgess, FRQA, Chief Compliance Officer at Pharm-Olam International. “The Bow Tie Method continues to become an integral component of every trial Pharm-Olam manages and conducts, from study level to functional level to procedural level.

The upcoming webinar will address these key questions:

  • What is GDPR?
  • What impact does GDPR have on your organization and on clinical trial conduct?
  • What do you need to have in place to comply with the regulation?
  • Are there differences in country-by-country interpretation?
  • How Pharm-Olam’s Bow Tie Method was utilized to manage our compliance readiness?
  • Where can you turn for assistance and adaptation during transition?

The webinar will be led by Pharm-Olam’s Data Protection Officer Natasa Spasic, who is trained and certified in GDPR regulations, and hosted by Dr. Yamin ‘Mo’ Khan, Executive Vice President, Global Clinical Development at Pharm-Olam.

Registration and attendance is open to the public. To register for the webinar, please visit:

About Pharm-Olam International
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. Pharm-Olam specializes in the conduct of clinical trials in Oncology, Infectious Disease and Vaccines, Rare Diseases, and Pediatric indications as well as continuing to support various other therapeutic areas within General Medicine. For further information about Pharm-Olam, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Colby
Visit website